Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody.
Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.
van der Ent
Cornelis K
CK
Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, KH 01.419.0, PO Box 85090, 3508 AB Utrecht, The Netherlands. k.vanderent@wkz.azu.nl
Hoekstra
Hans
H
Rijkers
Ger T
GT
D001229:Aspergillosis, Allergic Bronchopulmonary / Q000503:physiopathology / Q000628:therapy*; D002648:Child; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D007073:Immunoglobulin E / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D007073:Immunoglobulin E